SCHEMBL6816111

SCHEMBL6816111

CCOc1ccc(NC(=O)NC)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.73
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
POLB P06746 3/20 0.69
LMNA P02545 2/20 0.69
TDP1 Q9NUW8 2/20 0.69
CYP1A2 P05177 1/20 0.69
ALDH1A1 P00352 3/20 0.67
MAPK1 P28482 2/20 0.61
RAB9A P51151 7/20 0.60
NPC1 O15118 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
PKM P14618 1/20 0.60
GAA P10253 1/20 0.60
PLK1 P53350 1/20 0.59
MITF O75030 1/20 0.58
PAX8 Q06710 1/20 0.58
KDM4E B2RXH2 1/20 0.58
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10576308 0.91 MAPT (0.86) MAPTMEN1KMT2APOLBLMNA
SCHEMBL27710655 0.86 CA12 (0.65) MAPTMEN1KMT2APOLBLMNA
SCHEMBL6388672 0.86 MAPT (0.73) MAPTMEN1KMT2APOLBLMNA
SCHEMBL9037816 0.84 MAPT (0.71) MAPTMEN1KMT2APOLBLMNA
SCHEMBL4104467 0.84 MAPT (0.76) MAPTMEN1KMT2APOLBLMNA
Hydrochloric Acid SCHEMBL9004836 0.83 MAPT (0.69) MAPTMEN1KMT2APOLBLMNA
SCHEMBL4105709 0.83 MAPT (0.73) MAPTMEN1KMT2APOLBLMNA
SCHEMBL4113061 0.83 MAPT (0.73) MAPTMEN1KMT2APOLBLMNA
SCHEMBL4117849 0.83 MAPT (0.73) MAPTMEN1KMT2APOLBLMNA
Phenacetin SCHEMBL23280 0.81 KMT2A (1.00) MAPTMEN1KMT2APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200190034-A1 Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-06-18 US disclosed
WO-2019032563-A1 INHIBITORS OF BASE EXCISION REPAIR ACTIVITY AND THERAPEUTIC METHODS BASED THEREON THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-02-14 WO disclosed
US-7157601-B2 Alkylated urea and triaminotriazine compounds and phase change inks containing same XEROX CORPORATION (US) 2007-01-02 US disclosed
EP-1149072-B1 SULFONAMIDE HYDROXAMATES HOFFMANN LA ROCHE (CH) 2004-06-30 EP disclosed
US-6492394-B1 PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES SYNTEX (U.S.A.) LLC 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190034-A1 Inhibitors of Base Excision Repair Activity and Therapeutic Methods Based Thereon OGG1, UNG, MPG MAPT 3985/4885MEN1 1110/4885KMT2A 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.